ESC Premium Access

Short term effect of SGLT2 inhibitor, Dapagliflozin added on to standard therapy in decompensated heart failure patients with diabetes mellitus

Presentation

About the speaker

Doctor Masaki Nakagaito

University of Toyama, Toyama (Japan)
0 follower

6 more presentations in this session

Do beta-blockers improve one-year survival in heart failure patients with atrial fibrillation? Results from the ESC-HF Registry

Speaker: Doctor K. Ozieranski (Warsaw, PL)

Thumbnail

Heart failure subtypes and thromboembolic risk in patients with atrial fibrillation in the PREFER in AF registry

Speaker: Associate Professor J. Siller-Matula (Vienna, AT)

Thumbnail

Association between serum potassium and clinical outcomes in UK patients with heart failure

Speaker: Ms L. Qin (Gaithersburg, US)

Thumbnail

Presence of micro- and macroalbuminuria and association with cardiac mechanics in type 2 diabetes

Speaker: Doctor P. Jorgensen (Hellerup, DK)

Thumbnail

Empagliflozin reduces heart failure irrespective of control of blood pressure, low density lipoprotein cholesterol and HbA1c

Speaker: Doctor D. Fitchett (Toronto, CA)

Thumbnail

Access the full session

Fresh look at heart failure

Speakers: Doctor M. Nakagaito, Doctor K. Ozieranski, Associate Professor J. Siller-Matula, Ms L. Qin, Doctor P. Jorgensen...
Thumbnail

About the event

Image

ESC CONGRESS 2017

26 August - 30 August 2017

Sessions Presentations

This platform is supported by

logo Novo Nordisk